Blood test may aid early detection of Parkinson’s and guide treatment strategies
To date, Parkinson’s disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker for the diagnosis of this highly prevalent movement disorder. Researchers have now found initial evidence that a blood test to detect the alpha-synuclein protein is a viable, less invasive option to diagnose PD. The study appears in the Journal of Parkinson’s Disease, published by IOS Press, now part of Sage. The April 24, 2024 article is titled “Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson’s Disease Diagnosis and Duration.”
Lead investigators Annika Kluge, MD, and Eva Schaeffer, MD, both of the Department of Neurology, University Hospital Schleswig-Holstein, Campus Kiel and Kiel University, Kiel, Germany, say, “In recent years, it has been shown that the pathophysiological highly relevant protein alpha-synuclein, which accumulates in nerve cells, can also be detected in different body fluids and tissues of individuals with PD, for example in the cerebrospinal fluid or in skin tissue.”
In a previous publication this research team was able to show that alpha-synuclein can also be detected in the blood of PD patients by isolating small vesicles from neuronal cells (neuronal exosomes) from the blood and amplifying the alpha-synuclein they contain using a seed amplification assay (SAA).
Dr. Kluge adds, “With this current work we aimed to confirm that this blood test can detect alpha-synuclein in a larger group of individuals with PD and elucidate whether the amount of alpha-synuclein measured with the SAA changes during the course of the disease.”
Researchers analyzed cross-sectional blood samples from PD patients and compared these to samples of age- and gender-matched healthy controls using a blood-based SAA. In this study, 79 of 80 PD patients showed a positive seeding of alpha-synuclein derived from blood, while none of the healthy controls showed a positive blood test. This confirms that the alpha-synuclein blood marker is highly sensitive for PD.
When comparing subgroups of PD patients with different disease durations, longer disease duration was associated with lower alpha-synuclein seeding activity, showing that alpha-synuclein seeding activity changes over the course of the disease. It remains unclear whether and if so, how, alpha-synuclein seeding activity changes during the natural course of the disease.
Dr. Schaeffer and Dr. Kluge conclude, “There is currently no blood test for PD available in clinical practice. It is of course of great importance that the strong results of our cross-sectional and longitudinal analyses are validated and replicated in different labs. If the decline in seeding activity in blood was confirmed, it may influence further studies and our understanding of disease progression. In the long term, it is hoped that this blood test can be used to improve the diagnostic security and reliability in PD, even at early stages during which clinical diagnosis is difficult. Moreover, the impact on clinical studies needs to be considered, especially regarding the potential of antibody-based targeted treatments for PD.”
About the Journal of Parkinson’s Disease (JPD)
The Journal of Parkinson’s Disease (JPD) is dedicated to providing an open forum for original research in basic science, translational research, and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis, and treatment of Parkinson’s disease. It publishes research reports, reviews, short communications, and letters-to-the-editor, and offers very rapid publication and an affordable open-access option. JPD has a 2023 Journal Impact Factor of 4 according to Journal Citation Reports (Clarivate, 2024) and is published by IOS Press, now part of Sage. www.journalofparkinsonsdisease.com
About IOS Press
IOS Press is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement.
www.iospress.com
About Sage
Sage is a global academic publisher of books, journals, and library resources with a growing range of technologies to enable discovery, access, and engagement. Believing that research and education are critical in shaping society, 24-year-old Sara Miller McCune founded Sage in 1965. Today, we are controlled by a group of trustees charged with maintaining our independence and mission indefinitely. https://group.sagepub.com
[IOS Press news release] [Journal of Parkinson’s Disease abstract]